Figure 12, Mean plasma and heart concentration-time profiles of ML290 after an IP dose of 30 mg/kg in male C57BL/6 mice (N = 3)
Jingbo Xiao(National Center for Advancing Translational Sciences), Juan Marugán(National Institutes of Health), Xin Hu(Beijing Hospital), Wei Zheng(Liaoning Cancer Hospital & Institute), Noel Southall(National Institutes of Health), Marc Ferrer(National Institute of Biomedical Innovation, Health and Nutrition), Alexander I. Agoulnik(Florida International University), Zaohua Huang(Florida International University), Irina U. Agoulnik(University of South Florida), Catherine Z. Chen(National Institutes of Health)
Unknown
May 8, 2013
Cited by 0
Related Papers
Rethinking dog domestication by integrating genetics, archeology, and biogeography
|Proceedings of the National Academy of Sciences|2012|534
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
|British Journal of Pharmacology|2023|390
A transgenic insertion upstream of Sox9 is associated with dominant XX sex reversal in the mouse
|Nature Genetics|2000|351
Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia
|Cancer Cell|2015|348
Caveolin-1 Is Down-Regulated in Human Ovarian Carcinoma and Acts as a Candidate Tumor Suppressor Gene
|American Journal Of Pathology|2001|279